Browsing Clinical Studies by author "Ragulan, Chanthirika"
Now showing items 1-6 of 6
-
A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.
Smyth, EC; Nyamundanda, G; Cunningham, D; Fontana, E; Ragulan, C; et al. (OXFORD UNIV PRESS, 2018-12-01)BACKGROUND: Following neoadjuvant chemotherapy for operable gastroesophageal cancer, lymph node metastasis is the only validated prognostic variable; however, within lymph node groups there is still heterogeneity with risk ... -
Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes.
Ragulan, C; Eason, K; Fontana, E; Nyamundanda, G; Tarazona, N; et al. (NATURE PORTFOLIO, 2019-05-21)Previously, we classified colorectal cancers (CRCs) into five CRCAssigner (CRCA) subtypes with different prognoses and potential treatment responses, later consolidated into four consensus molecular subtypes (CMS). Here ... -
Comprehensive characterization of immune landscape of Indian and Western triple negative breast cancers.
Korlimarla, A; Ps, H; Prabhu, J; Ragulan, C; Patil, Y; et al. (ELSEVIER SCIENCE INC, 2022-11-01)PURPOSE: Triple-negative breast cancer (TNBC) is a heterogeneous disease with a significant challenge to effectively manage in the clinic worldwide. Immunotherapy may be beneficial to TNBC patients if responders can be ... -
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours.
Young, K; Lawlor, RT; Ragulan, C; Patil, Y; Mafficini, A; et al. (BMJ PUBLISHING GROUP, 2020-09-03)OBJECTIVE: A comprehensive analysis of the immune landscape of pancreatic neuroendocrine tumours (PanNETs) was performed according to clinicopathological parameters and previously defined molecular subtypes to identify ... -
Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial.
Fontana, E; Nyamundanda, G; Cunningham, D; Tu, D; Cheang, MCU; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2020-09-29)PURPOSE: Metastatic colorectal cancers (mCRCs) assigned to the transit-amplifying (TA) CRCAssigner subtype are more sensitive to anti-epidermal growth factor receptor (EGFR) therapy. We evaluated the association between ... -
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.
Vlachogiannis, G; Hedayat, S; Vatsiou, A; Jamin, Y; Fernández-Mateos, J; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2018-02-23)Patient-derived organoids (PDOs) have recently emerged as robust preclinical models; however, their potential to predict clinical outcomes in patients has remained unclear. We report on a living biobank of PDOs from ...